Glyten-Forte (Metformin 1000mg SR + Teneligliptin 20mg) – 10 Strips
Composition: Metformin 1000mg SR + Teneligliptin 20mg
Metformin + Teneligliptin is a combination of two antidiabetic medicines: Metformin and Teneligliptin. Metformin is an antidiabetic medication (biguanide). It works by lowering glucose production in the liver, delaying glucose absorption from intestines and increasing the body’s sensitivity to insulin. Teneligliptin is a dipeptidyl peptidase-4 inhibitor which works by increasing the release of insulin from pancreas and decreasing the hormones that raise blood sugar levels. This reduces both fasting and postmeal sugar levels. Together, they provide better control of blood sugar.
Diarrhoea, Nausea, Vomiting, Upset stomach, Headache, Nasal congestion (stuffy nose), Sore throat, Respiratory tract infection, Hypoglycaemia (low blood sugar level) in combination with insulin or sulphonylurea.
Teneligliptin should be administered carefully in the following:
- Patients with advanced liver failure (safety has not been established),
- Patients with congestive heart failure (NYHA category III-IV) (safety has not been established),
- Patients with pituitary insufficiency or adrenal insufficiency, poor nutritional state, starvation, an irregular dietary intake, or debilitating condition, intense muscle movement or excessive alcohol intake (may cause low blood sugar),
- Patients with history of abdominal surgery or with a history of bowel obstruction (may cause bowel obstruction),
- Patients with arrhythmia, severe bradycardia or its history, patients with heart disease such as congestive heart failure or patients with low serum potassium, congenital prolonged QT syndrome, history of Torsades de pointes or patients using antiarrhythmic drugs (may cause QT prolongation),
- Patients using an insulin secretagogue (e.g., sulfonylurea) (risk of severe hypoglycaemia).
Teneligliptin is contraindicated in the following:
- Any patient with a known hypersensitivity to teneligliptin or any of the components in the formulation,
- Severe ketosis, diabetic coma or history of diabetic coma, type 1 diabetic patients,
- Patients with severe infection, surgery, severe trauma (blood sugar control should preferably be done by insulin).
Pharmacodynamics & Mechanism of Action
Teneligliptinis a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by teneligliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signalingpathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, teneligliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.
Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Store the medicine at 15-30°C.